Assessing the clinical benefit, safety, and patient-reported outcomes with the use of the PAHcare™ digital platform in pulmonary arterial hypertension: a pilot study.

Autor:	Peñate GP; Unidad Multidisciplinar Vascular Pulmonar, Servicio de Neumología, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain.; Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain., Parra NO; Unidad Multidisciplinar de Hipertensión Pulmonar, Servicio de Cardiología, Hospital Universitario 12 de Octubre, Madrid, Spain.; Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12), Madrid, Spain., Morera JAD; Servicio de Neumología, Hospital Universitario Miguel Servet, Zaragoza, Spain., Meñaca AM; Servicio de Neumología, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain., Ramón ML; Servicios de Neumología y Cardiología, Unidad de Hipertensión Pulmonar, Complejo Asistencial Universitario de Salamanca, Salamanca, Spain., Menéndez SC; Clinical Research Department, Ferrer, Barcelona, Spain., Marrero FL; Unidad Multidisciplinar Vascular Pulmonar, Servicio de Neumología, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain., de la Cal SG; Servicio de Neumología, Hospital Universitario Miguel Servet, Zaragoza, Spain., Ghadban-Garrido C; Servicio de Neumología, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain., Tolosana PR; Servicio de Neumología, Hospital Universitario Miguel Servet, Zaragoza, Spain., Puentes JM; Servicios de Neumología y Cardiología, Unidad de Hipertensión Pulmonar, Complejo Asistencial Universitario de Salamanca, Salamanca, Spain., Aguayo RA; Clinical Research Department, Ferrer, Barcelona, Spain., Mahdavi H; Digital Health & Technology, Ferrer, Barcelona, Spain., Jeanneret GB; Corporate Medical Department, Ferrer, Barcelona, Spain., Subías PE; Unidad Multidisciplinar de Hipertensión Pulmonar, Servicio de Cardiología, Hospital Universitario 12 de Octubre, Madrid, Spain.; Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain.
Jazyk:	angličtina
Zdroj:	Frontiers in public health [Front Public Health] 2024 Feb 16; Vol. 12, pp. 1335072. Date of Electronic Publication: 2024 Feb 16 (Print Publication: 2024).
DOI:	10.3389/fpubh.2024.1335072
Abstrakt:	Introduction: Digital health interventions, particularly mobile health platforms, have shown promise in supporting patients with respiratory conditions, but their application in pulmonary arterial hypertension (PAH) remains limited. We aimed to assess the feasibility, acceptability, and potential clinical benefit of the novel PAHcare™ digital platform as a patient-centred intervention for PAH management through a prospective, single-arm, multicenter pilot study conducted on 53 patients diagnosed with PAH who used the platform for 6 months. Methods: The primary objective was to assess the impact on Health-Related Quality of Life (HRQoL) through questionnaires. Secondary objectives included evaluating clinical outcomes, including disease progression, PAH signs and symptoms, the 6-min walking test, and the patient's symptom perception. Additionally, we assessed patient satisfaction and engagement with the PAHcare™ platform, interaction with health coaches, retention, costs and healthcare resource utilisation (HCRU), and safety through monitoring device incidents. Results: Minimal changes in HRQoL and clinical outcomes were observed over 6 months. A noteworthy 92.4% of patients actively used the platform in the first month, maintaining high usage throughout the study. Patient satisfaction was substantial, with more than half of the patients expressing excellence in service quality, willingness to reuse the platform, and fulfilment of their needs. Health coach interaction was high, with 76% of patients initiating contact within the first week. User retention rates were 70%, with prevalent ongoing usage and interaction with healthcare professionals even after the study. In terms of HCRU and costs, the study showed no significant changes in PAH-related hospital admissions, clinical visits, or tests. Finally, the low number of device-related incidents indicated platform safety. Conclusion: This pilot study provides compelling evidence supporting the feasibility and acceptability of the PAHcare™ digital platform to empower patients to manage their disease and significantly enhance their overall experience with PAH. Competing Interests: PE has received consulting and lecture fees by Ferrer Internacional S.A. (Barcelona, Spain), Gossamer Bio., AOP Health, Janssen, and MSD. GP has received consulting fees by Ferrer Internacional S.A. (Barcelona, Spain). RA, HM, and GB are employees of Ferrer Internacional (Barcelona, Spain). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Peñate, Parra, Morera, Meñaca, Ramón, Menéndez, Marrero, de la Cal, Ghadban-Garrido, Tolosana, Puentes, Aguayo, Mahdavi, Jeanneret and Subías.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu